Lau Wai Kwan, Goh Bey Hing, Kadir Habsah Abdul, Shu-Chien Alexander Chong, Muhammad Tengku Sifzizul Tengku
Experimental Therapeutics Center, Institute of Pharmaceuticals and Nutraceuticals Malaysia, Blok 5-A, Halaman Bukit Gambir, Penang 11700, Malaysia.
Biomolecular Research Group, Biochemistry Program, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur 50603, Malaysia.
Molecules. 2015 Dec 12;20(12):22301-14. doi: 10.3390/molecules201219847.
Numerous documented ethnopharmacological properties have been associated with Swietenia macrophylla (Meliaceae), with its seed extract reported to display anti-hypoglycemic activities in diabetic rats. In the present study, three compounds isolated from the seeds of S. macrophylla were tested on a modified ELISA binding assay and showed to possess PPARγ ligand activity. They were corresponded to PPARγ-mediated cellular response, stimulated adipocyte differentiation but produced lower amount of fat droplets compared to a conventional anti-diabetic agent, rosiglitazone. The up-regulation of adipocytes was followed by increased adipocyte-related gene expressions such as adiponectin, adipsin, and PPARγ. The S. macrophylla compounds also promoted cellular glucose uptake via the translocation of GLUT4 glucose transporter.
大叶桃花心木(楝科)具有众多已被记录的民族药理学特性,其种子提取物据报道在糖尿病大鼠中显示出抗低血糖活性。在本研究中,从大叶桃花心木种子中分离出的三种化合物在改良的ELISA结合试验中进行了测试,并显示具有PPARγ配体活性。它们与PPARγ介导的细胞反应相对应,刺激脂肪细胞分化,但与传统抗糖尿病药物罗格列酮相比,产生的脂肪滴数量较少。脂肪细胞的上调伴随着脂肪细胞相关基因表达的增加,如脂联素、脂肪酶和PPARγ。大叶桃花心木化合物还通过GLUT4葡萄糖转运蛋白的转位促进细胞对葡萄糖的摄取。